Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
manelimab
- Development stage
- Phase 1
- Lead developer
- Biocad
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Manelimab (BCD-135) is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), also known as CD274. By binding to PD-L1, manelimab blocks its interaction with the PD-1 receptor on T cells, thereby inhibiting an immune checkpoint pathway that tumors use to evade immune detection. This mechanism enhances the body’s antitumor immune response. Manelimab is being developed by Biocad for the treatment of advanced solid tumors, including non-small cell lung cancer, bladder cancer, small cell lung cancer, renal cell carcinoma, and melanoma. The drug has been evaluated in phase 1 clinical trials for these indications.
- Other names
- manelimabBCD-135BCD135BCD 135
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on manelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on manelimab.